Washington State Hospital Association Advances Key Healthcare Legislation
Discover how WSHA is shaping healthcare legislation in Washington, advocating for vital bills and addressing pressing issues like drug pricing and medical oversight.
Impact of Fifth Circuit Ruling on Hospital Payments and 340B Eligibility
Explore the Fifth Circuit's ruling affecting hospital payments and 340B eligibility, highlighting key regulatory compliance challenges for healthcare providers.
CMS Updates on Medicare Drug Price Negotiation and 340B Rebate Litigation
CMS announces changes to Medicare drug price negotiations; ongoing litigation surrounds 340B rebate model and state drug pricing laws, affecting Medicare Advantage plans and Part D reimbursement.
CMS 2026 Medicare OPPS and ASC Final Rule Advances Site-Neutral Payments and Expands Price Transparency
CMS finalizes 2026 Medicare outpatient payment rule with expanded site-neutral payments, enhanced hospital price transparency, and telehealth supervision provisions affecting hospitals and ASCs nationwide.
US Drug Pricing Negotiations, Telehealth Flexibilities, 340B Pilot, and ACA Subsidies Update
Explore recent US developments on federal drug price negotiation expansion to commercial plans, DEA telehealth prescribing extensions, the 340B rebate pilot launch, and ACA subsidy debates in the Senate impacting insurance and healthcare markets.
CMS Finalizes CY 2026 OPPS-ASC Rule with Key Medicare Reimbursement Updates
CMS releases the Calendar Year 2026 OPPS-ASC Final Rule, impacting Medicare reimbursement rates for hospital outpatient services, radiopharmaceuticals, and 340B drug pricing.
Hospitals Sue HHS Over 340B Pilot Program Changes
Hospitals challenge HHS's 340B pilot shifting drug discounts to a rebate system, citing financial risks and regulatory concerns.
CMS Launches Voluntary Medicaid MFN Drug Pricing Model; Trump-Era Manufacturer Agreements Expand
CMS unveils the GENERous Medicaid payment model introducing MFN drug pricing, alongside expanded Trump administration drug pricing agreements and key regulatory updates for 2026.
340B Program Linked to Higher ACA Silver Plan Premiums, Study Finds
Study finds the 340B Drug Pricing Program contributes to higher Affordable Care Act Silver Plan premiums, affecting insurance costs and subsidies.
Trump Executive Order on Drug Pricing Targets Medicare, 340B Reimbursements
Summary of Trump's executive order directing HHS to reduce prescription drug costs, focusing on Medicare reimbursement for 340B drugs, IRA drug pricing provisions, and CMS premium stabilization efforts.